KoBioLabs Inc
KoBioLabs, Inc. provides microbiome therapeutics for metabolic, immune, and brain diseases. The company was founded in 2014 and is based in Seoul, South Korea.
KoBioLabs Inc (348150) - Total Liabilities
Latest total liabilities as of September 2025: ₩43.82 Billion KRW
Based on the latest financial reports, KoBioLabs Inc (348150) has total liabilities worth ₩43.82 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
KoBioLabs Inc - Total Liabilities Trend (2018–2024)
This chart illustrates how KoBioLabs Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
KoBioLabs Inc Competitors by Total Liabilities
The table below lists competitors of KoBioLabs Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Huxen Corp
TW:2433
|
Taiwan | NT$3.22 Billion |
|
Accelya Solutions India Limited
NSE:ACCELYA
|
India | ₹1.99 Billion |
|
Clal Insurance Enterprises Holdings Ltd
TA:CLIS
|
Israel | ILA173.51 Billion |
|
Globex Mining Enterprises Inc
OTCQX:GLBXF
|
USA | $132.21K |
|
Inission AB (publ)
ST:INISS-B
|
Sweden | Skr1.11 Billion |
|
Ihlas Gayrimenkul Proje Gelistirme ve Ticaret AS
IS:IHLGM
|
Turkey | TL3.17 Billion |
Liability Composition Analysis (2018–2024)
This chart breaks down KoBioLabs Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.78 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.47 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how KoBioLabs Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for KoBioLabs Inc (2018–2024)
The table below shows the annual total liabilities of KoBioLabs Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩64.18 Billion | +21.54% |
| 2023-12-31 | ₩52.80 Billion | +13.30% |
| 2022-12-31 | ₩46.61 Billion | +217.12% |
| 2021-12-31 | ₩14.70 Billion | +367.10% |
| 2020-12-31 | ₩3.15 Billion | -96.46% |
| 2019-12-31 | ₩88.95 Billion | +320.26% |
| 2018-12-31 | ₩21.16 Billion | -- |